Skip to main content
NIH funding notice RFA-HG-15-039

Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44)

Closed on August 7, 2016.

Posted
October 27, 2015
Close date
August 7, 2016
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
1
1 new
First-year cost
$848,530
Institutions
1
1 contact PI

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. ARIMA GENOMICS, INC.1

Most frequent study sections

  1. Special Emphasis Panel (ZHG1 HGR-N (J2))1
1 award under RFA-HG-15-039 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2017Commercialization of a low-cost user-friendly DNA preparation kit that produces chromosome-span contiguity from conventional short-read sequencing​​ for a wide range of applications1R44HG009584-01Selvaraj, SiddarthARIMA GENOMICS, INC., CAFirst-year cost $848,530Study section ZHG1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-14-0.3.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-HG-15-039: Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44) | ScienceDex | ConductScience